Are there any results of innovative drugs in Hengrui Pharma?

After more than ten years of medical innovation, Hengrui Pharma has begun to enter the harvest period. Two targeted drugs, apatinib and pyrrolidine, as well as the tumor immune drug Karezhu (PD- 1 monoclonal antibody), have rapidly grown into large varieties with annual sales of 654.38+0 billion yuan. Later, many potential varieties were laid out. It is believed that the width and depth of its layout are very competitive, and some goals are not just "China New" but "Global New". In 2020, the British medical information company IDEA Pharma released the ranking of medical innovation index and medical invention index in 2020, and Hengrui Pharma made the list for the first time, ranking 13 and 15 respectively in the world. Hengrui was also selected as the top 50 pharmaceutical companies in the world, ranking 47th.